Ares Commercial Real Estate Insider Shake‑Up: What Professionals Should Know This Week

Modern suburban homes

If your morning coffee pairs well with a dash of market intrigue, today’s spotlight lands squarely on Ares Commercial Real Estate Corporation (NYSE:ACRE). The company’s CEO & Director, Bryan Donohoe, recently sold US$107k worth of shares at an average price of US$4.93—a move that trimmed his personal stake by roughly 13%.

Insider activity doesn’t always spell trouble, but it always sparks questions. And in today’s evolving market landscape, Florida real estate agents, mortgage professionals, and investment‑minded specialists nationwide should keep an eye on moves like these. Understanding market behavior is part of staying competitive—something we take seriously at Cameron Academy as we help professionals stay informed, licensed, and ahead of industry shifts.

A Bigger Pattern? Understanding ACRE Insider Behavior

This isn’t Donohoe’s first sale of the year. Earlier, he sold approximately US$133k worth of shares at US$5.68 per share—meaning his earlier sale happened at a stronger price point. While insider selling is common, repeated sales without any insider buying can raise eyebrows among seasoned investors.

According to the data, insiders at Ares Commercial Real Estate made no purchases in the past 12 months. That doesn’t automatically signal danger, but it does create a tone of caution from within the leadership ranks.

See the Full Insider Activity Chart

Want to explore every insider transaction from the past year? View the interactive chart here and dig into dates, prices, and individual trades.

How Much Skin Do Insiders Have in the Game?

Insider ownership sits at about 1.6%—worth roughly US$4.6 million. While not insignificant, it isn’t especially high either. Lower insider ownership often correlates with lower long-term alignment, though it doesn’t always indicate poor performance.

As the Simply Wall St analysis suggests, many companies show stronger internal confidence through larger insider holdings. ACRE’s numbers are conservative but not alarming.

What Should Professionals Take Away?

Insiders sold stock recently, and none showed buying activity. Combined with modest insider ownership, the indicators suggest a measured caution. Still, insider selling by itself is not a forecast of decline—it’s simply one piece of a much larger market puzzle.

For professionals navigating real estate, finance, and investment spaces, this serves as a reminder of the importance of market literacy. Whether you’re evaluating REITs, shaping a portfolio, or watching economic signals, staying informed is essential. If you’re growing your career or expanding your license portfolio, Cameron Academy provides the educational backbone to help keep you competitive and current.

More From the Source

Explore the full analysis, discover small-cap stocks insiders are buying, or try their free portfolio tools:

Insider‑Bought Small Caps
Try the Free Portfolio Companion
Contact the Editorial Team

And as always: this information isn’t financial advice—but it does help you stay sharp, curious, and one step ahead as you navigate the day’s headlines.

More Articles

Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!

The Remote Work Revolution: Redefining Real Estate

Imagine a morning where the commute is just a few steps from your bedroom to your home office. This is the reality for many in today's post-pandemic world, where remote work has become a staple of the modern workforce.

By |December 2, 2024|Categories: Article, Real Estate, Remote Work|Tags: , |0 Comments

CRISPR: The Future of Gene Editing and Its Clinical Implications

CRISPR technology has become the frontrunner in genome editing, surpassing earlier methods like zinc finger nucleases and transcription activator-like effector nucleases. The recent FDA approval of the CRISPR-Cas9 drug, exa-cel, marks a significant milestone particularly for treating sickle cell disease and transfusion-dependent beta thalassemia.

By |December 1, 2024|Categories: Article, Biotechnology, Medicine|Tags: , |0 Comments

AI Revolution in Oncology: Transformative Potential or Overhyped?

In recent years, artificial intelligence has emerged as a revolutionary tool in the field of oncology. AI's integration into healthcare transcends buzzwords, transforming cancer diagnosis, treatment personalization, and drug discovery.

AI in Radiology: A Double-Edged Sword

The rapid advancements in artificial intelligence (AI) are transforming the landscape of radiology, promising to enhance diagnostic accuracy and support personalized medicine. However, as this technology becomes more integral to medical imaging, it brings with it a host of ethical and societal considerations that cannot be ignored.

Humanity at the Crossroads: Ethical Implications of AI in Medicine

AI's promise in healthcare is undeniable, with its ability to uncover hidden disease patterns and predict illnesses. However, the reliance on historical data can exacerbate existing biases, particularly affecting marginalized communities such as the LGBTQIA+ and certain ethnic and racial groups.

The Future of Telemedicine: Challenges and Opportunities Beyond the Pandemic

Telemedicine stands out as a transformative force, offering a lifeline to patients and providers alike. As we move beyond the pandemic, the challenge is to integrate this technology without escalating costs or overshadowing the indispensable role of in-person consultations.

By |November 30, 2024|Categories: Article, Healthcare, Technology|Tags: , |0 Comments